Skip to content

Information for students, faculty and staff regarding COVID-19. (Updated: 26 February 2021)

Published: 18 Jan, 2016

New biomarkers for improved treatment of severe heart- and lung disease

NEWS New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary arterial hypertension (PAH). This according to a doctoral dissertation at Umeå University.

PIcture of Anna Sandqvist, Umeå University.
Doctoral student Anna Sandqvist at Umeå University. Credit: Pia Seidel.

“We have discovered that the biomarkers that we have investigated have a particularly high diagnostic value in PAH, by comparing with heart failure and healthy individuals. These biomarkers have the potential to be used as a routine diagnostic strategy and in the evaluation of PAH patients. Since the levels of these markers in the blood are reflecting the clinical efficacy of PAH specific medical treatment, there is good hope that they soon can be used routinely to measure treatment response. The results are so far based on around 20 PAH patients, which means that more research is necessary on larger patient groups,” says Anna Sandqvist, doctoral student at the Department of Pharmacology and Clinical Neuroscience and author of the dissertation.

PAH is an unusual heart- and lung disease that first and foremost affects the finest branches of the arteries in the lungs. The arteries are thickened and become stiff, the blood flow is reduced which leads to hypertension – increased blood pressure – and hypoxia of the pulmonary arteries – a deprivation of adequate oxygen supply. Both heart and lung functions are affected and many patients develop right heart failure. PAH is a very serious condition which, at present, has a poorer prognosis than many cancers and there are only a few appropriate methods for treatment and evaluation.

Today, PAH patients are treated with medications that dilate the blood vessels and, hence, reduce the pulmonary artery pressure. Anna Sandqvist has studied a new drug to treat this disease called vardenafil. Vardenafil belongs to the same group of pharmaceuticals as Viagra and can be used both in diagnostics and in the treatment of PAH.

“Vardenafil has a fast onset and powerful effect on the blood vessels of the lungs. But if vardenafil is used in combination with the endothelin receptor antagonist bosentan – another pharmaceutical often used by patients with PAH – the effect of treatment can be hampered and lead to the need of increasing the dosage of vardenafil. Therapeutic drug monitoring may thus become necessary to check the pharmaceutical concentrations in the blood in order to optimise the dosage,” says Anna Sandqvist.

Anna Sandqvist grew up in Umeå, a mid-sized town in northern Sweden. Apart from her doctoral studies at the Department of Pharmacology and Clinical Neuroscience at Umeå University, she works as a pharmacist at the University Hospital of Umeå. 

Read a digital publication of the dissertation

About the public defence of the dissertation:

On Friday 22 January, Anna Sandqvist at the Department of Pharmacology and Clinical Neuroscience at Umeå University, defends her dissertation with the title: Vardenafil and methylarginines in pulmonary hypertension. Opponent: Professor Amrita Ahluwalia, Centre for Clinical Pharmacology, Barts and London Queen Mary's School of Medicine and Dentistry, London. Head supervisor: Gerhard Wikström.
The public defence of the dissertation takes place at 13:00 in Lecture Hall B, floor 9, Tandläkarhögskolan.

For more information, please contact:

Anna Sandqvist, Department of Pharmacology and Clinical Neuroscience, Unit of Clinical Pharmacology, Umeå UniversityPhone: +46 73-369 9601, +46 90-785 35 61

Photo credit: Wikipedia

Editor: Anna Lawrence